Reports

Reversal of adriamycin resistance by verapamil in human ovarian cancer

See allHide authors and affiliations

Science  01 Jun 1984:
Vol. 224, Issue 4652, pp. 994-996
DOI: 10.1126/science.6372095

Abstract

The effectiveness of adriamycin in the treatment of ovarian cancer and other human tumors has been limited by the development of drug resistance. Verapamil, a calcium channel blocking agent, completely reversed adriamycin resistance in human ovarian cancer cells with moderate (three- to sixfold) degrees of resistance and partially reversed resistance in highly (150-fold) resistant cells. The potentiating effect of verapamil was due to inhibition of adriamycin efflux in the resistant cells. These results have led to a clinical trial of adriamycin and verapamil in refractory ovarian cancer patients.